Trade Regeneron Pharmaceuticals, Inc. - REGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 4.91 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1061.87 |
| Open | 1068.7 |
| 1-Year Change | 46.51% |
| Day's Range | 1068.7 - 1089.14 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 1062.58 | 1.04 | 0.10% | 1061.54 | 1101.15 | 1059.10 |
| Jul 24, 2024 | 1059.99 | 4.52 | 0.43% | 1055.47 | 1065.78 | 1049.14 |
| Jul 23, 2024 | 1054.91 | -10.25 | -0.96% | 1065.16 | 1074.55 | 1051.32 |
| Jul 22, 2024 | 1064.32 | -5.22 | -0.49% | 1069.54 | 1076.52 | 1059.52 |
| Jul 19, 2024 | 1063.71 | -1.42 | -0.13% | 1065.13 | 1075.43 | 1057.59 |
| Jul 18, 2024 | 1062.13 | -26.52 | -2.44% | 1088.65 | 1097.32 | 1061.05 |
| Jul 17, 2024 | 1084.63 | -6.35 | -0.58% | 1090.98 | 1098.27 | 1075.49 |
| Jul 16, 2024 | 1091.51 | 17.11 | 1.59% | 1074.40 | 1100.55 | 1072.17 |
| Jul 15, 2024 | 1081.00 | -8.45 | -0.78% | 1089.45 | 1098.44 | 1076.68 |
| Jul 12, 2024 | 1099.78 | 20.46 | 1.90% | 1079.32 | 1105.56 | 1079.32 |
| Jul 11, 2024 | 1079.90 | 17.06 | 1.61% | 1062.84 | 1090.80 | 1062.84 |
| Jul 10, 2024 | 1069.81 | 14.15 | 1.34% | 1055.66 | 1071.99 | 1048.17 |
| Jul 9, 2024 | 1051.64 | 0.00 | 0.00% | 1051.64 | 1058.19 | 1039.24 |
| Jul 8, 2024 | 1047.69 | 26.47 | 2.59% | 1021.22 | 1053.63 | 1021.22 |
| Jul 5, 2024 | 1033.33 | 8.43 | 0.82% | 1024.90 | 1040.01 | 1022.34 |
| Jul 3, 2024 | 1022.66 | -15.57 | -1.50% | 1038.23 | 1043.46 | 1009.55 |
| Jul 2, 2024 | 1044.08 | -10.87 | -1.03% | 1054.95 | 1056.97 | 1027.99 |
| Jul 1, 2024 | 1056.02 | 16.26 | 1.56% | 1039.76 | 1068.45 | 1039.76 |
| Jun 28, 2024 | 1050.90 | 0.34 | 0.03% | 1050.56 | 1056.11 | 1040.16 |
| Jun 27, 2024 | 1047.88 | -21.24 | -1.99% | 1069.12 | 1070.38 | 1046.00 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Regeneron Company profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.| Industry: | Bio Therapeutic Drugs |
777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com